Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV005382842 | SCV006034566 | uncertain significance | Inborn genetic diseases | 2025-01-21 | criteria provided, single submitter | clinical testing | The c.6897C>A (p.H2299Q) alteration is located in exon 40 (coding exon 39) of the NIPBL gene. This alteration results from a C to A substitution at nucleotide position 6897, causing the histidine (H) at amino acid position 2299 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |